Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tiomolibdate choline - Monopar Therapeutics

Next Previous
Drug Profile

Tiomolibdate choline - Monopar Therapeutics

Alternative Names: ALXN-1840; ATN-224; Bis(choline)tetrathiomolybdate; Bis-choline tetrathiomolybdate; Decuprate; WTX-101

Latest Information Update: 26 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Michigan
  • Developer Alexion AstraZeneca Rare Disease; Attenuon; Cancer Research UK
  • Class Antineoplastics; Heavy metals; Neuroprotectants; Small molecules
  • Mechanism of Action Chelating agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hepatolenticular degeneration; Amyotrophic lateral sclerosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Hepatolenticular degeneration
  • No development reported Amyotrophic lateral sclerosis
  • Discontinued Breast cancer; Malignant melanoma; Multiple myeloma; Prostate cancer; Solid tumours

Most Recent Events

  • 23 Sep 2025 Pharmacodynamics data from a phase-II trial in Hepatolenticular degeneration released by Monopar Therapeutics
  • 31 Mar 2025 AstraZeneca plans to file a regulatory submission for Hepatolenticular degeneration (PO) in early 2026
  • 14 Nov 2024 Monopar Therapeutics plans a meeting with the US FDA

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top